Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. (Q51696425)

9 April 2018

title

Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. (English)

1 reference

9 April 2018

1 reference

1 reference

3

Anne Schuchat

1 reference

9 April 2018

Alicia M Fry

1

Alicia M Fry

1 reference

9 April 2018

Cynthia G Whitney

5

Cynthia G Whitney

1 reference

9 April 2018

Elizabeth Zell

2

Elizabeth R Zell

1 reference

9 April 2018

Jay C. Butler

4

Jay C Butler

1 reference

9 April 2018

language of work or name

English

0 references

publication date

1 December 2002

1 reference

9 April 2018

published in

Vaccine

1 reference

9 April 2018

volume

21

1 reference

9 April 2018

issue

3-4

1 reference

9 April 2018

page(s)

303-311

1 reference

9 April 2018

Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Pneumococcal conjugate vaccination for adults: why it's important for children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Active bacterial core surveillance of the emerging infections program network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Pneumococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Safety of revaccination with pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

Pneumococcal antibody levels one decade after immunization of healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900451-6

7 January 2021

10.1016/S0264-410X(02)00451-6

Identifiers

DOI

1 reference

9 April 2018

PubMed ID

12450706

1 reference

9 April 2018